Vanda (0LKB) AI Stock Analysis

Vanda

(LSE:0LKB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Fanapt Commercial MomentumFanapt is showing durable commercial traction, supported by higher sales, prescription growth, and stronger new-to-brand demand. Expansion into bipolar I disorder and broader sales-force coverage can extend the product’s addressable market and help sustain branded revenue over the next several quarters.

Negative Factors

Elevated Cash BurnRapid cash depletion combined with an expectation of higher annual burn creates a meaningful funding and runway risk. Continued investment in launches and clinical programs may require difficult capital-allocation decisions, especially if new products do not scale quickly enough to offset spending.

Vanda (0LKB) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $229.15M
Dividend Yield: ―
Average Volume (3M): 7,067
Price to Earnings (P/E): -0.8
Beta (1Y): 1.20
Revenue Growth: 8.11%
EPS Growth: -222.50%
Country: UK
Employees: 533
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Vanda Business Overview & Revenue Model

Company Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-2...

Vanda Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:-3.33%|Next Earnings Date:Feb 09, 2027

Earnings Call SentimentPositive

The call was broadly positive, supported by 24% third-quarter revenue growth, strong Fanapt prescription trends, positive NEREUS and HETLIOZ clinical results, the expected BYSANTI launch, the Quimilza regulatory milestone, and declining quarterly operating expenses. These positives were partly offset by a larger year-to-date net loss, a substantial cash balance decline, expected higher 2026 cash burn, continued generic pressure on HETLIOZ, constrained early NEREUS revenue, and ongoing regulatory proceedings.

Positive Updates

Third-Quarter Revenue Growth

Total revenues were $69.8 million in the third quarter of 2026, increasing 24% compared to $56.3 million in the third quarter of 2025 and 38% compared to $50.5 million in the second quarter of 2026. The increases were primarily due to higher HETLIOZ revenue from the timing of specialty pharmacy purchases and customer shipments, along with Fanapt growth from the bipolar I commercial launch.

Negative Updates

Higher Year-to-Date Net Loss

For the first nine months of 2026, Vanda recorded a net loss of $133.6 million compared with a net loss of $79.3 million in the same period of 2025. The 2026 loss included $0.4 million of income tax expense, compared with a $21.4 million income tax benefit in the comparable 2025 period.

Company Guidance

Vanda updated its full year 2026 total revenue guidance, expecting total revenues from Fanapt, BYSANTI, HETLIOZ, PONVORY, and NEREUS of greater than $240 million; NEREUS revenue is likely to be less than $10 million for the full year of 2026, while NEREUS total prescriptions and unique prescribers in Q3 2026 increased by over 100% versus Q2 2026. Vanda is not providing 2026 cash guidance at this time, but it is likely that Vanda's 2026 cash burn will be greater than the cash burn in 2025. Operating expenses decreased by 18% to $93.3 million from $114.3 million in Q2 of 2026 and are expected to decrease further in future quarterly periods. BYSANTI is expected to launch in the fourth quarter of 2026, Quimilza could be ready with commercial product a few months after December, with the goal of being on the market in the first half of 2027, and the BYSANTI MDD study is expected to complete in the first half of 2027.

Vanda Risk Analysis

Vanda disclosed 61 risk factors in its most recent earnings report. Vanda reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.Our business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.Q2, 2026

Vanda Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0LKB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OMER	48Neutral	$1.33B	9.65	-109.40%	―	―	―
ALEC	45Neutral	$327.65M	-2.01	-531.04%	―	-82.91%	6.27%
MREO	44Neutral	$46.21M	-1.59	-74.76%	―	-100.00%	44.94%
ALDX	40Underperform	$33.80M	-1.45	-53.14%	―	―	54.84%
EDIT	34Underperform	$410.06M	-3.57	-196.63%	―	20.83%	73.89%

* Healthcare Sector Average

Performance Comparison

GB:0LKB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0LKB	Vanda Pharmaceuticals	3.77	-0.64	-14.42%
OMER	Omeros Corporation	18.44	11.27	157.18%
ALDX	Aldeyra Therapeutics	0.56	-4.67	-89.29%
EDIT	Editas Medicine Inc.	2.67	-0.39	-12.75%
MREO	Mereo Biopharma	0.29	-1.57	-84.46%
ALEC	Alector	2.21	0.77	53.47%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Vanda AI Stock Analysis